Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of multiple myeloma, version 2.0
Journal for ImmunoTherapy of Cancer · 2026-11 · 14 (11) · e016142
DOI: 10.1136/jitc-2026-016142 ↗Kurz gefasst
Leitlinie in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 06.11.2026. Verfasst von Yi Lin und 20 weiteren Autor:innen. Beteiligte Einrichtung: Mayo Clinic, Rochester, Minnesota, USA lin.yi@mayo.edu mdhodapk@fredhutch.org. Die Arbeit nennt 267 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
The treatment landscape for multiple myeloma (MM) is continually evolving, with numerous immunotherapy treatment options currently available. Most recently, chimeric antigen receptor (CAR) T-cell therapies, T-cell engager (TCE) bispecific antibody therapies, and antibody-drug conjugates (ADCs) targeting B-cell maturation antigen (BCMA) or G protein-coupled receptor class C group 5 member D (GPRC5D) have demonstrated durable clinical benefits and are approved for patients with relapsed/refractory MM. Additionally, anti-CD38 monoclonal antibody-based combination therapies with and without immunomodulatory agents and proteasome inhibitors remain standards of care for patients with both newly diagnosed and relapsed/refractory MM. There are many practical and clinical considerations to take into account for CAR T-cell, TCE, and ADC therapy administration, safety management, and treatment sequencing, making clinical decisions complex and nuanced. To provide guidance to the hematology and medical oncology community, the Society for Immunotherapy of Cancer convened a multidisciplinary panel of experts to develop a clinical practice guideline. This guideline contains expert-developed evidence-based and consensus-based clinical recommendations on the utilization of approved immunotherapies for the treatment of MM, with the goal of improving patient outcomes.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Mayo Clinic, Rochester, Minnesota, USA lin.yi@mayo.edu mdhodapk@fredhutch.org.
- Independent Contributor, San Jose, California, USA.
- Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
- Greco-Hainsworth Centers for Research, Tennessee Oncology, Nashville, Tennessee, USA.
- Independent Contributor, Dallas, Texas, USA.
- Department of Hematology/Oncology, University of California San Francisco, San Francisco, California, USA.
Zitieren
APA
Lin, Y., Aiello, J., Avigan, D., Berdeja, J. G., Biru, Y., Chari, A., Christenson, L. H., Costello, C., Garfall, A. L., Green, D. J., Hansen, D. K., Jagannath, S., Krishnan, A., Kumar, S., Lonial, S., Munshi, N. C., Patel, K. K., Raje, N., Usmani, S. Z., …, & Dhodapkar, M. V. (2026). Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of multiple myeloma, version 2.0. Journal for ImmunoTherapy of Cancer, 14(11), e016142. https://doi.org/10.1136/jitc-2026-016142
Vancouver
Lin Y, Aiello J, Avigan D, Berdeja JG, Biru Y, Chari A, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of multiple myeloma, version 2.0. Journal for ImmunoTherapy of Cancer. 2026;14(11):e016142. doi:10.1136/jitc-2026-016142
BibTeX
@article{Lin2026,
author = {Lin, Yi and Aiello, Jack and Avigan, David and Berdeja, Jesus G and Biru, Yelak and Chari, Ajai and Christenson, Lisa Hwa and Costello, Caitlin and Garfall, Alfred L and Green, Damian J and Hansen, Doris K and Jagannath, Sundar and Krishnan, Amrita and Kumar, Shaji and Lonial, Sagar and Munshi, Nikhil C and Patel, Krina K and Raje, Noopur and Usmani, Saad Z and Vij, Ravi and Dhodapkar, Madhav V},
title = {Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of multiple myeloma, version 2.0},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2026},
volume = {14},
number = {11},
pages = {e016142},
doi = {10.1136/jitc-2026-016142}
}
EUVIMED